Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2021

Pan Dong, Hu Angela Y, Antonia Scott J, Li Chuan-Yuan

Abstract excerpt

INTRODUCTION: Identification of patients who can benefit from immune checkpoint blockade (ICB) therapy is key for improved clinical outcome. Recently, U.S. Food and Drug Administration approved tumor mutational burden (TMB) high (TMB-H or TMB ≥ 10) as a biomarker for pembrolizumab treatment of solid tumors. We intend to test the hypothesis that mutations in select genes may be a better predictor of NSCLC response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Ferroptosis and cancer prognosis

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Source

Open in PubMed Open full text

Identifiers

PMID: 33307194
DOI: 10.1016/j.jtho.2020.11.021
PMCID: PMC7920921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.PMID 33307194Read ↗

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.Semantic proximity Read ↗

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute StudySemantic proximity Read ↗

Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancerSemantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.Semantic proximity Read ↗

Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis.Semantic proximity Read ↗

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.